peripheral neuropathies

Patisiran for hereditary transthyretin amyloidosis polyneuropathy in V122I and T60A genotypes is reported with variant-specific outcomes. Findings describe measurable changes in neurologic function and patient-reported domains under routine multicenter cond...

In hereditary transthyretin amyloidosis with polyneuropathy, the siRNA therapy patisiran reduces hepatic TTR production, aiming to slow axonal injury. In individuals with V122I or T60A variants, results indicate neuropathy can stabilize or improve on treatm...

Patisiran for hereditary transthyretin amyloidosis polyneuropathy with V122I or T60A variants was evaluated in a phase IV multicenter setting, reporting genotype-specific outcomes under routine practice. Results described changes in neuropathy severity and ...